Anthropic's S-1, LLM price cuts, vLLM tool calls and a skin-cancer CNN: four developer stories in one Daily Diff
Four developer stories from one Monday: Anthropic filed a public Form S-1 that reports first-half 2026 revenue of $16.3 billion and a net loss of $80.7 billion, most of it a fair-value line on convertible notes, with the price and share count still blank; OpenAI and Anthropic cut LLM prices and the filing gives Anthropic's own account of its cuts; Ubicloud reports that constrained decoding lifts Kimi and DeepSeek tool-call schema accuracy on vLLM from 92 percent to 100 percent; and a dermatologist's 200-lesion test found a ten-year-old image network beat GPT-6 Astra and Claude Fable 5.1, 62 percent to 42 percent, with caveats he lists himself.
Four developer stories from one Monday: Anthropic filed a public Form S-1 that reports first-half 2026 revenue of $16.3 billion and a net loss of $80.7 billion, most of it a fair-value line on convertible notes, with the price and share count still blank; OpenAI and Anthropic cut LLM prices and the filing gives Anthropic's own account of its cuts; Ubicloud reports that constrained decoding lifts Kimi and DeepSeek tool-call schema accuracy on vLLM from 92 percent to 100 percent; and a dermatologist's 200-lesion test found a ten-year-old image network beat GPT-6 Astra and Claude Fable 5.1, 62 percent to 42 percent, with caveats he lists himself. Each claim is attributed to its primary source, nothing is investment or medical advice, and the verdict is NEEDS REVIEW.
Read the written edition (English) ↗
What this video covers
- Anthropic's Form S-1 was accepted by SEC EDGAR on October 26, 2026 at 09:00 New York time. It is a preliminary filing: the price range, share counts and several of the newest figures are blank, and the company has applied to list Class A shares on the Nasdaq Global Select Market under the symbol ANT.
- The S-1's summary table reports revenue of $16,286 million for the first six months of 2026 (all of 2025: $4,585 million), compute and infrastructure expenses of $8,945 million, an operating loss of $693 million (operating margin -4 percent), an adjusted (non-GAAP) operating income of $1,618 million that adds back stock-based compensation of $2,185 million and other items, and a net loss of $80,748 million. $72,388 million of the loss is the change in fair value of convertible notes, derivative liabilities and SAFEs, which the filing says was primarily driven by an increase in the company's enterprise valuation.
- The S-1 also reports a $1.5 billion Bartz settlement (approved by the court in July 2026), cash and cash equivalents of $112.4 billion at June 30, 2026, and that Claude Enterprise users without Claude Code spent under $75 a month on average in the three months to September 30, 2026, while the top 5 percent of Claude Enterprise users who used Claude Code spent about 20 times that.
- OpenAI says GPT-5.6 Luna became 80 percent cheaper on July 30, 2026, and lists GPT-6.1 Sol at $2 input, $10 output and $0.10 cached input per million tokens, one fifth of GPT-6 Astra's standard input and output prices. Anthropic says Opus 5.5 costs about 40 percent less to run than Opus 5; its S-1 says the September reductions combined lower prices and better efficiency while preserving margins.
- Ubicloud (October 20, 2026) measured 92 percent tool-call schema accuracy for Kimi K2.6 on vLLM 0.28, meaning 2 in 25 tool calls failed, and 100 percent after enabling constrained decoding (vLLM's tool-strict-level flag, vLLM 0.31) on Kimi and DeepSeek models; vLLM keeps it off by default because users reported problems with some models.
- Dr Magnus Lynch (Guy's Hospital, King's College London; October 25, 2026) tested GPT-6 Astra, Claude Fable 5.1 and a fine-tuned Inception v3 CNN on 200 biopsy-proven lesions: the CNN named the right diagnosis for 125 (62 percent), each chatbot for 42 percent; the CNN named 13 of 30 melanomas as first choice against 8 and 11. He lists the caveats himself, including small numbers and one run per chatbot; this is not medical advice.
Questions and answers
What does Anthropic's S-1 filing report about revenue and losses?
Anthropic's Form S-1, accepted by the SEC on October 26, 2026, reports revenue of $16,286 million for the first six months of 2026, against $4,585 million for all of 2025. The operating loss was $693 million, an adjusted non-GAAP operating income was $1,618 million, and the net loss was $80,748 million. Of that, $72,388 million is a change in the fair value of convertible notes, which the filing says was primarily driven by a higher company valuation. The price range and share counts are blank.
Why did OpenAI and Anthropic cut LLM prices, and what does GPT-6.1 Sol cost?
OpenAI says GPT-5.6 Luna became 80 percent cheaper on July 30, 2026, and lists GPT-6.1 Sol at $2 input, $10 output and $0.10 cached input per million tokens, one fifth of GPT-6 Astra's standard prices. Anthropic says Opus 5.5 costs about 40 percent less to run than Opus 5, and its S-1 says compute efficiency let it cut prices while preserving margins. Max Woolf points to competition from open-weight models.
How can I raise tool-call accuracy when serving open models with vLLM?
Ubicloud measured only 92 percent tool-call schema accuracy for Kimi K2.6 on vLLM 0.28, so about 2 in 25 calls failed. Turning on constrained decoding, available as the tool-strict-level flag in vLLM 0.31, stops the model from sampling tokens that break the tool's JSON schema, and Ubicloud measured 100 percent on Kimi and DeepSeek models. vLLM keeps it off by default because users reported problems with some models.
Did a ten-year-old CNN really beat GPT-6 Astra and Claude Fable 5.1 at skin cancer diagnosis?
In Dr Magnus Lynch's October 25, 2026 test of 200 biopsy-proven lesions, a fine-tuned Inception v3 network named the right diagnosis for 125 (62 percent) and each chatbot for 42 percent. For melanoma first choice it scored 13 of 30 against 8 and 11. Lynch notes small numbers, one run per chatbot and that regulated products perform better than this baseline. It is a blog test and nothing in it is medical advice.
What was The Daily Diff's verdict on these four stories?
The Daily Diff's verdict was NEEDS REVIEW. Niko's reason is that the Anthropic filing has a loss on paper, a profit in an adjusted measure and a lot of blanks, the price story rests partly on one blogger's reading, and the skin-cancer test is two hundred cases run once. The advice is to read the filing yourself, re-run your LLM cost estimates against current price pages, and check your tool-call settings if you serve open models.
Transcript
Where does an eighty billion dollar loss come from?
0:00 Sixteen billion dollars of revenue in six months sounds like a company printing money. Anthropic's own prospectus lists an eighty billion dollar net loss for those same six months. In this video, four stories. What is inside Anthropic's S one, and where does that loss come from? Why did OpenAI and Anthropic cut their prices? Can one server flag fix open models? And how does a ten year old image model beat the newest chatbots at spotting
0:28 skin cancer? The skin cancer study was drafted with a tool from the company in story one. I will come back to that at the end. It's Monday, October twenty sixth, and this is The Daily Diff. A prospectus is the document a company files before it sells shares to the public. Think of it as release notes for a whole business, where every line has a lawyer's fingerprints on it. Anthropic, the company that makes Claude, filed its first one today.
What did Anthropic file, and what is blank?
0:51 Story one. Just after nine on Monday morning, New York time, Anthropic filed a Form S one with the S E C. It names the Nasdaq symbol A N T. It is a preliminary filing, so the share price, the share count and the newest quarter's revenue are still blank. Revenue was about forty one million dollars in twenty twenty three and about four point six billion in twenty twenty five. In the first six months of this year alone it was sixteen billion.
1:19 Then the loss. The operating loss for those six months was about seven hundred million dollars, four percent of revenue. The net loss was eighty billion, and seventy two billion of that is one line, the change in fair value of convertible notes. In plain words, as the company becomes worth more, the notes it owes become worth more, and the accounts record that as a loss. The filing also reports an adjusted operating profit of one point six
1:44 billion, which adds back stock pay and a few other items. The same filing shows the copyright bill. In September twenty twenty five Anthropic agreed to settle the Bartz authors' class action for one point five billion dollars, which has its own line in the expense table. That settlement came up in our OpenAI pirated books story a month ago. Here is the part for developers. For the three months to the end of September, the filing says Claude Enterprise
2:08 users who did not use Claude Code spent under seventy five dollars a month on average. The top five percent who did use it spent about twenty times that. The ownership is unusual. A trust elects a majority of the board through its own class of shares, and a company owned by the founders holds one special share worth fifty point one percent of the votes.
Why did OpenAI and Anthropic cut their prices?
2:28 Story two. Max Woolf, who blogs as minimaxir, lined up every price change from OpenAI and Anthropic since June, and the post passed three hundred eighty points on Hacker News. OpenAI's own post says that on July thirtieth GPT five point six Luna got eighty percent cheaper. By September twenty ninth, OpenAI listed GPT six point one Sol at two dollars in and ten dollars out per million tokens, a fifth of the price of its top model, Astra.
2:57 Anthropic says Opus five point five costs about forty percent less to run than Opus five, the price war we covered in September. Woolf's own reaction was to downgrade. He cut his Codex plan to a fifth of the usage limit, because the same model now stretched four times further. He also notes that in coding agents, cache reads are most of the token bill. Anthropic's filing gives its own account. It says the September cuts combined a lower price with better efficiency,
3:23 and that compute efficiency let it keep its margins. After the cheaper Opus four point five, it says, quarterly revenue growth went from forty eight percent to one hundred thirty two percent, with other factors helping. Woolf's explanation is open weight models. Kimi K three point one Pro, released October twenty third, lists at the same two dollars and ten dollars as GPT six point one Sol. So re-run your cost estimates against today's price pages.
3:49 In agent work the cached input line matters most, and OpenAI cut that one in half for Sol. Story three. Ubicloud, a cloud company, published a fix for tool calls in open
Can one server flag fix open models?
4:00 models. Serving Kimi K two point six on vLLM zero point twenty eight, only ninety two percent of tool calls matched the tool's schema, which means two in every twenty five failed. The fix is constrained decoding. The server stops the model from picking any token that would break the tool's JSON schema. In vLLM zero point thirty one it is a flag called tool strict level, and Ubicloud measured one hundred percent on Kimi and DeepSeek. vLLM keeps it off by default because users reported problems with some models,
4:33 such as GLM five point one. Ubicloud's point is that the engine and its settings change the quality you see.
How does an old model beat the newest chatbots?
4:39 Story four. Dermatologist Magnus Lynch, who works at Guy's Hospital in London, gave GPT six Astra and Claude Fable five point one a test of two hundred biopsied skin lesions, each as a close up plus a dermoscopy image. He also fine tuned Inception v three, an image network Google published in twenty fifteen, for about twenty minutes on one GPU. It was right on sixty two percent of the lesions. Each chatbot was right on forty two percent. The chatbots had favourites.
5:08 GPT six Astra called seventy five lesions basal cell carcinoma when twenty five were. On melanoma, the one that matters most, the small network named thirteen of thirty first, against eight and eleven. Lynch lists the caveats himself. Two hundred cases is small, each chatbot ran once, and the network is a baseline that regulated products beat. It runs in a phone browser through WebGPU and nothing is uploaded. Nothing here is medical advice.
5:37 And the thread from the start. Lynch writes that the analysis and first drafts were produced with Claude Code, Anthropic's coding tool, and that one of the two chatbots he tested is also Anthropic's. If you'd rather read this than hear me say it, the diff lands in your inbox every morning, free at the daily diff dot dev, link below. So today's verdict is NEEDS REVIEW.
What gets the NEEDS REVIEW stamp?
5:56 I'd review it because the Anthropic filing has a loss on paper, a profit in an adjusted measure and a lot of blanks, the price story rests partly on one blogger's reading, and the skin cancer test is two hundred cases run once. And that's the diff for today. I'm Niko from Axrisi. Merge responsibly.
Sources
- Anthropic, PBC Form S-1 (registration statement)U.S. Securities and Exchange Commission (EDGAR)
- EDGAR filing index for accession 0001628280-26-067168U.S. Securities and Exchange Commission (EDGAR)
- OpenAI and Anthropic cut their LLM prices by up to 80% within a few months. Why?Max Woolf (minimaxir.com)
- Advancing the price-performance frontier with GPT-5.6OpenAI
- Introducing GPT-6.1 SolOpenAI
- Claude Opus 5.5Anthropic
- Fixing Tool-Call Accuracy in vLLMUbicloud
- A 10-year-old CNN outperforms frontier LLMs for skin cancer diagnosisDr Magnus Lynch (lynchlab.net)
- Kimi K3.1 ProOpenRouter



